| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of Fmoc-L-photo-methionine are proteins and binding partners within native cellular environments. Upon UV irradiation, the diazirine group generates a highly reactive carbene intermediate that forms covalent bonds with nearby amino acid residues, enabling capture and identification of protein-protein interactions, ligand-receptor complexes, and traditionally undruggable targets.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies using photo-methionine probes demonstrate efficient photo-crosslinking upon UV irradiation at 360 nm. The diazirine group is stable in the dark and in cell lysates, with activation yielding carbene that reacts with C-H, N-H, and O-H bonds within Angstrom distances. Incorporation into peptides enables identification of binding partners via mass spectrometry after enrichment. |
| ln Vivo |
In vivo applications of Fmoc-L-photo-methionine are emerging for mapping protein interactions in living cells and model organisms. Studies demonstrate successful crosslinking in bacterial and mammalian cell culture systems, with UV activation enabling spatial and temporal control of interaction capture. This approach is accelerating drug discovery for probing cellular mechanisms and target validation.
|
| Enzyme Assay |
Cell-free photoaffinity labeling assays incorporate the compound into synthetic peptides or small-molecule probes. Probes (1-100 uM) are incubated with purified protein or lysate in binding buffer for 30-60 minutes in the dark, then irradiated at 360 nm for 5-15 minutes using a photoreactor. Crosslinked samples are digested and analyzed by LC-MS/MS to identify binding sites and interaction partners.
|
| Cell Assay |
Cell-based photoaffinity labeling uses cells transfected or incubated with probes containing this photocrosslinker. Cells are incubated in dark for 1-4 hours to allow binding, then irradiated with UV light (360 nm, 5-15 minutes) to induce crosslinking. Cells are lysed, crosslinked complexes are enriched via affinity tags (biotin/His), and analyzed by Western blot or mass spectrometry for interaction mapping.
|
| Animal Protocol |
Animal studies for photo-methionine derivatives are conducted in C. elegans, Drosophila, or mice. Animals are fed or injected with compound-labeled peptides/probes, allowed to distribute for 1-24 hours, then exposed to UV light (360 nm) through transparent tissues or via fiber optics. Tissues are harvested for downstream proteomic analysis to identify interaction networks in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of photocrosslinking probes depend on the peptide/probe scaffold. The diazirine group is metabolically stable prior to UV activation, with no significant activation in the dark. Incorporation into peptides may extend half-life, but the probe itself is used for crosslinking rather than as a therapeutic agent. Distribution is scaffold-dependent, with tissue penetration varying by molecular size.
|
| Toxicity/Toxicokinetics |
Toxicological profiles of diazirine-based photocrosslinkers are not well-characterized, as they are used at low concentrations for labeling studies rather than therapeutic applications. The carbene intermediate generated upon UV exposure is highly reactive but short-lived, minimizing off-target damage. Standard safety precautions for UV exposure and chemical handling apply. Not approved for human use.
|
| References | |
| Additional Infomation |
This compound has molecular formula C21H21N3O4 and molecular weight 379.41, with purity ≥95%. It is a solid used in peptide synthesis, photoaffinity labeling, and structural biology for mapping protein-protein interactions. Storage at -20degC desiccated is recommended. For research use only, not for therapeutic applications.
|
| Molecular Formula |
C21H21N3O4
|
|---|---|
| Molecular Weight |
379.41
|
| Exact Mass |
379.153
|
| CAS # |
945859-89-2
|
| PubChem CID |
137946927
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
28
|
| Complexity |
609
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N[C@H](C(=O)O)CCC1(C)N=N1)=O)CC1C2C=CC=CC=2C2=CC=CC=C12
|
| InChi Key |
QKMQUEIDJLPYHS-SFHVURJKSA-N
|
| InChi Code |
InChI=1S/C21H21N3O4/c1-21(23-24-21)11-10-18(19(25)26)22-20(27)28-12-17-15-8-4-2-6-13(15)14-7-3-5-9-16(14)17/h2-9,17-18H,10-12H2,1H3,(H,22,27)(H,25,26)/t18-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-(3-methyldiazirin-3-yl)butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6357 mL | 13.1784 mL | 26.3567 mL | |
| 5 mM | 0.5271 mL | 2.6357 mL | 5.2713 mL | |
| 10 mM | 0.2636 mL | 1.3178 mL | 2.6357 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
